Elevance Health (ELV) Stock Analysis
NYQ · Healthcare · Healthcare Plans
$396.45
+0.36 (+0.09%)
ELV Interactive Price Chart & Trading Signals
ELV Stock Snapshot — Valuation, Risk & Technical Signals
ELV Key Fundamentals, Analyst Targets & Company Profile
Key Financial Ratios
Market Cap
$85.98B
P/E Ratio
17.53
Forward P/E
13.42
PEG Ratio
1.30
P/B Ratio
1.92
EPS
$22.62
Dividend Yield
1.74%
52W Range
$274.84 – $436.24
Beta
0.70
Volume
0.1M
ROE
11.1%
Profit Margin
2.5%
Revenue Growth
1.4%
Gross Margin
26.0%
EV/EBITDA
9.56
Analyst Target
$451.38
The trailing price-to-earnings ratio stands at 17.5x. Forward P/E of 13.4x implies earnings expansion expected. Price-to-book is 1.92x. EV/EBITDA sits at 9.56x. Market capitalization is $85.98B. Revenue is growing at 1.4% on a trailing basis. Earnings are compressing at -13.1%. Profit margins are 2.5%. Return on equity is 11.1%. Beta of 0.70 indicates defensive profile.
Analyst Consensus
Recommendation
Buy
Low Target
$393.00
Mean Target
$451.38
High Target
$492.00
Based on 21 analysts
About Elevance Health
Elevance Health, Inc., together with its subsidiaries, operates as a health benefits company in the United States. The company operates in four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to individual, employer group risk-based and fee-based, BlueCard, Medicare, Medicaid, and FEP members; health products; a broad array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, and supplemental health insurance benefits. The company also operates in the pharmacy services business; and markets and offers pharmacy services, including home delivery and specialty pharmacies, claims adjudication, formulary management, pharmacy networks, rebate administration, a prescription drug database, and member services, as well as infusion services and injectable therapies through ambulatory infusion centers. In addition, it provides healthcare related services and capabilities, including specialty care enablement and utilization management support for specialized clinical domains; behavioral health and comprehensive care management services; palliative care services and management; virtual care; and payment integrity, subrogation, clinical data exchange through its HealthOS platform, research and data, reporting and clinical analytics, information technology, and business process support services, as well as manages home health, post-acute institutional management, and durable medical equipment costs; and supports plans in managing home and community-based services. The company provides its services under the Anthem Blue Cross and Blue Shield, Wellpoint, and Carelon brands. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health, Inc. in June 2022. Elevance Health, Inc. was incorporated in 2001 and is based in Indianapolis, Indiana.
ELV Deep Dive Analysis
Bottom Line
Verdict
OvervaluedBest for
General investorWatch out for
Premium valuation, Earnings declineNon-zero inputs
4/5Counts non-zero values for price, P/E, beta, macro risk, and revenue growth; zero may mean unavailable or be a genuine zero.
Elevance Health, Inc. (ELV) trades above our multi-model fair value estimate of $282.72 by approximately 28.7%. Trailing P/E: 17.5x. Profitability signals include profit margin of 2.5% and return on equity of 11.1%. Recent growth metrics show revenue growth of 1.4% and earnings growth of -13.1%. Risk profile: defensive beta of 0.70. Consensus: buy.
Valuation, Growth & Risk
Valuation
Overvalued
P/E 17.5x
Price is above what fundamentals suggest.
Growth
Stable
Rev 1.4%
Revenue is moving sideways.
Risk
Low
Beta 0.70
Movement is likely to track the broader market.
Valuation Snapshot
Elevance Health, Inc. (ELV) trades above our multi-model fair value estimate of $282.72 by approximately 28.7%. The trailing price-to-earnings ratio stands at 17.5x. Forward P/E of 13.4x suggests earnings compression ahead. Price-to-sales is 0.4x. Price-to-book is 1.9x. EV/EBITDA sits at 9.6x. Market capitalization is $85.98B.
Why it matters: Paying a premium works only if the company keeps growing faster than expected.
Growth & Profitability
Revenue is growing at 1.4% on a trailing basis. Earnings are compressing at -13.1%. Profit margins are 2.5%. Return on equity is 11.1%. Return on assets is 3.8%.
Why it matters: Stable revenue is fine, but watch for margin pressure that could limit profit growth.
Risk Profile
Beta of 0.70 indicates defensive profile. Net debt position is $-6469998592.00.
Why it matters: Lower risk means steadier returns, but often with less upside in bull markets.
Analyst Context
Analyst consensus target of $451.38 implies 13.9% upside. Target range spans $393.00 to $492.00. 21 analysts cover the stock. Consensus recommendation: buy.
Why it matters: Analyst targets reflect what professionals expect over 12 months. A wide gap between price and target can mean the market disagrees with the consensus.
Data Methodology & Sources
Market Data (Facts)
- Price, volume, and market cap: Yahoo Finance (may be delayed)
- P/E, EPS, revenue, and debt: Yahoo Finance fundamentals
- Analyst estimates: Yahoo Finance (coverage and update times vary)
- Insider transactions: Yahoo Finance (reporting may be delayed)
QuantSoar Model (Derived)
- Fair value: available outputs from seven models; outliers are filtered using MAD (k=3.5), then combined with fixed model weights.
- Margin of Safety = (Fair Value − Displayed Price) / Displayed Price × 100
- Composite Score: 40% Value + 30% Momentum + 30% Risk
- Verdict Gauge: Base 50 + Valuation (up to ±25) + Whale sentiment (up to ±10) + Insider buying (+5) + Macro risk (up to ±10) + Technical signal (up to ±10). Analyst consensus is separate.
Model outputs are estimates based on available data and are not investment advice. Cross-check with primary sources before making investment decisions.
ELV Overvalued
Elevance Health, Inc. (ELV) trades above our multi-model fair value estimate of $282.72 by approximately 28.7%.
Frequently Asked Questions
ValuationIs ELV stock overvalued right now?
ValuationWhat is ELV fair value based on current fundamentals?
RiskHow risky is ELV compared with other stocks?
GrowthIs ELV still growing?
AnalystWhat do analysts think about ELV?
DividendDoes ELV pay a dividend?
CatalystWhat could change the investment case for ELV?
Related Stocks
About the Author
Phasakorn Traklang (Peach) — Founder
Phasakorn Traklang (Peach) is the founder of QuantSoar, bringing expertise in SEO, web development, and technical analytics to build an AI-powered investment platform accessible to retail investors worldwide.
Connect on LinkedInInvestment Disclaimer: Tax treatment can depend on tax residence, account type, and tax year. This information is general and is not personal tax or investment advice. SEC
Data: Yahoo Finance / SEC EDGAR / Alpha Vantage / Finnhub. AI outputs verified against source data.